涓€鎵规經鍦ㄦ柊鍐犵梾姣�妫�绐佽泲鐧芥姂鍒跺姂鐨勭爺绌�
鍗楁柟绉戞妧澶у鐢熺墿绯诲壇鏁欐巿鐜嬪啝瀹囩爺绌跺湗闅娿€侀啱瀛搁櫌鏁欐巿寮靛仴鐮旂┒鍦橀殜鑱悎娣卞湷澶у绺介啱闄㈡潕娴烽饭鐮旂┒鍦橀殜鍒濇绡╅伕鍑轰竴鎵规柊鍨嬪啝鐙€鐥呮瘨妫樼獊铔嬬櫧(spike glycoprotein)娼涘湪鎶戝埗鍔戯紝鐩搁棞鎴愭灉鐧煎竷鍦ㄩ爯鍗扮増骞宠嚭Research Square銆� 鐮旂┒琛ㄦ槑锛屾柊鍐犵梾姣掑埄鐢ㄥ叾鍖呰啘涓婄殑妫樼獊铔嬬櫧璀樺垾浜洪绱拌優鑶滃彈楂旇泲鐧紸CE2锛屽緸鑰屼镜鏌撲汉椤炵窗鑳烇紝寮曠櫦鍤撮噸鐨勫懠鍚搁亾鎰熸煋鐧ョ媭銆傞樆姝㈢梾姣掓绐佽泲鐧借垏浜洪鍙楅珨铔嬬櫧ACE2鐩镐簰浣滅敤鏄爺鐧兼湁闂滆棩鐗┿€佹姉楂斿拰鐤嫍鐨勯噸瑕佹柟鍚戙€� 鏂板啝鐥呮瘨妫樼獊铔嬬櫧鎶戝埗鍔戠閬哥瓥鐣� 鑱悎鐮旂┒鍦橀殜鐐哄姞蹇湁闂滄姂鍒跺姂鐨勭櫦鐝撅紝閲囩敤鈥滆€佽棩鏂扮敤(Drug repurposing)鈥濈殑绛栫暐锛屼互鍏枊鐨凴BD-ACE2寰╁悎鐗╂櫠楂旂祼妲嬬偤闈堕粸锛岄€氶亷鍚屾簮寤烘ā(Homology Modeling)銆佽▓绠楁杓斿姪钘ョ墿瑷▓(Computer-aided drug design, CADD)鍜岃櫅鎿閬�(Virtual screening)绛夎▓绠楃敓鐗╁鏂规硶锛岀閬镐簡杩�15000鍊嬪皬鍒嗗瓙鍖栧悎鐗┿€傞€欎簺鍖栧悎鐗╁寘鍚獶rugbank鍖栧悎鐗╁韩涓墍鏈夌殑FDA鎵规簴钘ョ墿锛屼互鍙奣CMSP鍖栧悎鐗╁韩涓殑澶╃劧娲绘€х敘鐗┿€傜爺绌跺湗闅婂皣閫欎簺鍖栧悎鐗╄垏鐥呮瘨妫樼獊铔嬬櫧鍙楅珨绲愬悎绲愭鍩熼€茶鍒嗗瓙灏嶆帴锛岀櫦鐝句竴鎵圭祼鍚堥潪甯哥穵瀵嗙殑鍖栧悎鐗╋紝濡侱igitoxin,Nilotinib,Lemborexant锛孯altegravir,Bisindigotin鍜� Evodiamine绛夈€� Digitoxin鑸囨绐佽泲鐧界祼鍚堟ā寮忓湒 Bisindigotin鑸囨绐佽泲鐧界祼鍚堟ā寮忓湒
鍗楁柟绉戞妧澶у
2021-04-10